

P R E S S R E L E A S E

FOR IMMEDIATE DISTRIBUTION

NEA APPOINTS DAVID M. MOTT AS GENERAL PARTNER

Biotech Industry Leader Brings Deep Domain Expertise to Healthcare Practice

Chevy Chase, MD – September 17, 2008 – New Enterprise Associates, Inc. (NEA), a leading global venture capital firm, today announced that David M. Mott has joined the firm as General Partner. Mr. Mott, a top biotechnology executive who led industry giant MedImmune to the largest biotech acquisition to date when it was bought by AstraZeneca Plc in 2007, will focus on biotechnology and specialty pharmaceutical investing within NEA's east coast healthcare practice.

“Dave has long been a galvanizing force in the biotechnology industry – he is a global thought leader who has contributed enormously to innovation in life sciences,” said Peter J. Barris, Managing General Partner of NEA. “His broad sector expertise and strong ties within the biopharma community add substantial depth to NEA's healthcare practice, and we are delighted to welcome him to the firm.”

Prior to joining NEA, Mr. Mott was President and Chief Executive Officer of MedImmune, subsidiary of AstraZeneca Plc, and Executive Vice President of AstraZeneca. He joined MedImmune in 1992 and served in roles of increasing responsibility including Chief Operating Officer, Chief Financial Officer, President and Chief Executive Officer. Under his leadership, MedImmune became one of the largest biotechnology companies in the industry. When the company was acquired in 2007, annual revenues were about \$1.3 billion, with annual R&D investments totaling about \$450 million. Mr. Mott also founded the company's venture capital subsidiary, MedImmune Ventures, Inc., in 2002, and chaired its investment committee through his departure from MedImmune.

Previously, Mr. Mott was a Vice President in the Health Care Investment Banking Group at Smith Barney, Harris Upham & Co. Inc. In this role, Mr. Mott's activities included public and private equity and debt financings as well as merger and acquisition work for biotechnology, healthcare services, and medical product and device companies.

Mr. Mott is currently a director of specialty pharmaceuticals company, Shire plc (NASDAQ: SHPGY) and of next generation antibiotic company, Rib-x Pharmaceuticals. He is a member of the Management Executives' Society and a Senior Advisor to Chatham House, the London-based international and economic affairs institution. He is also a member of the St. Albans School Governing Board. He is a former board member of Ambit Biosciences, Conceptis Technologies, and MedImmune, Inc. and has served on numerous industry trade group and not-for-profit boards, including the Biotechnology Industry Organization (BIO) and the High Tech Council of Maryland. Mr. Mott holds a bachelor's degree in economics and government from Dartmouth College.

About NEA

New Enterprise Associates, Inc. (NEA) is a leading venture capital firm focused on helping entrepreneurs create and build major new enterprises that use technology to improve the way we live, work and play. Since its founding in 1978, the firm has followed the same core principles: supporting its entrepreneurs, providing an excellent return to its limited partners, and practicing its profession with the highest standards and respect. Through its affiliated funds, NEA focuses on investments at all stages of a company's development, from seed stage through IPO. With approximately \$8.5 billion in committed capital, NEA's experienced management team has invested in over 600 companies, of which more than 160 have gone public and more than 240 have been acquired. NEA has U.S. offices in Chevy Chase, Maryland; Menlo Park, California; and Baltimore, Maryland. In addition, New Enterprise Associates (India) Pvt. Ltd. has an office in Bangalore, India and New Enterprise Associates (Beijing), Ltd. has offices in Beijing and Shanghai, China. For additional information, visit www.nea.com.

###

Contact:

New Enterprise Associates

Kate Barrett

+1-301-272-2318; kbarrett@nea.com